AR083588A1 - Forma cristalina de 13-[(n-tert-butoxicarbonil)-2’-o-hexanoil-3-fenilsoserinil]-10-deacetilbaccatina iii y proceso para prepararla - Google Patents

Forma cristalina de 13-[(n-tert-butoxicarbonil)-2’-o-hexanoil-3-fenilsoserinil]-10-deacetilbaccatina iii y proceso para prepararla

Info

Publication number
AR083588A1
AR083588A1 ARP110103990A ARP110103990A AR083588A1 AR 083588 A1 AR083588 A1 AR 083588A1 AR P110103990 A ARP110103990 A AR P110103990A AR P110103990 A ARP110103990 A AR P110103990A AR 083588 A1 AR083588 A1 AR 083588A1
Authority
AR
Argentina
Prior art keywords
tert
phenylososinin
hexanoil
deacetilbaccatine
butoxicarbonil
Prior art date
Application number
ARP110103990A
Other languages
English (en)
Inventor
Daniele Ciceri
Andrea Gambini
Maurizio Ricotti
Nicola Sardone
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Publication of AR083588A1 publication Critical patent/AR083588A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

13-[(N-tert-butoxicarbonil)-2’-O-hexanoil-3-fenilisoserinil]-10-deacetilbaccatina III en una forma cristalina; es decir la forma cristalina A.Reivindicación 3: La forma cristalina de 13-[(N-tert-butoxicarbonil)-2’-O-hexanoil-3-fenilisoserinil]-10-deacetilbaccatina III de acuerdo con la reivindicación 2, caracterizada porque la Forma cristalina A tiene un difractograma de XRPD que se caracteriza por los siguientes picos: 6,1; 9,1; 10,1; 10,6; 11,7; 13,0; 18,5; 19,8; 22,0 grados 2-q ± 0,2º.
ARP110103990A 2010-10-29 2011-10-28 Forma cristalina de 13-[(n-tert-butoxicarbonil)-2’-o-hexanoil-3-fenilsoserinil]-10-deacetilbaccatina iii y proceso para prepararla AR083588A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10189373A EP2447268A1 (en) 2010-10-29 2010-10-29 Crystalline form of 13-[(N-tert-butoxycarbonyl)-2'-O-hexanoyl-3-phenylisoserinyl]-10-deacetylbaccatin III

Publications (1)

Publication Number Publication Date
AR083588A1 true AR083588A1 (es) 2013-03-06

Family

ID=43886731

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103990A AR083588A1 (es) 2010-10-29 2011-10-28 Forma cristalina de 13-[(n-tert-butoxicarbonil)-2’-o-hexanoil-3-fenilsoserinil]-10-deacetilbaccatina iii y proceso para prepararla

Country Status (16)

Country Link
US (1) US9062018B2 (es)
EP (2) EP2447268A1 (es)
JP (1) JP5744215B2 (es)
KR (2) KR101577177B1 (es)
CN (1) CN103209983B (es)
AR (1) AR083588A1 (es)
AU (1) AU2011322572B2 (es)
CA (1) CA2814907C (es)
DK (1) DK2632926T3 (es)
ES (1) ES2528374T3 (es)
MX (1) MX2013004722A (es)
PL (1) PL2632926T3 (es)
PT (1) PT2632926E (es)
RU (1) RU2546661C2 (es)
SI (1) SI2632926T1 (es)
WO (1) WO2012055952A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1457492B1 (en) 2001-11-29 2008-01-02 Daiichi Sankyo Company, Limited Crystals of taxane derivative and process for their production
ES2663495T3 (es) * 2005-02-18 2018-04-13 Abraxis Bioscience, Llc Fármacos con hidrofobicidad mejorada para incorporación en dispositivos médicos
NZ576355A (en) 2006-10-20 2012-04-27 Scinopharm Singapore Pte Ltd Process for making crystalline anhydrous docetaxel
KR20150136137A (ko) 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도

Also Published As

Publication number Publication date
US9062018B2 (en) 2015-06-23
KR20130086618A (ko) 2013-08-02
CA2814907A1 (en) 2012-05-03
RU2013124011A (ru) 2014-12-10
AU2011322572B2 (en) 2015-02-19
AU2011322572A1 (en) 2013-05-02
KR20150099614A (ko) 2015-08-31
PT2632926E (pt) 2015-02-09
CN103209983A (zh) 2013-07-17
ES2528374T3 (es) 2015-02-09
WO2012055952A1 (en) 2012-05-03
EP2632926A1 (en) 2013-09-04
MX2013004722A (es) 2013-08-29
DK2632926T3 (en) 2015-01-12
CA2814907C (en) 2015-02-03
PL2632926T3 (pl) 2015-04-30
JP2013540798A (ja) 2013-11-07
KR101577177B1 (ko) 2015-12-14
US20140303240A1 (en) 2014-10-09
SI2632926T1 (sl) 2015-03-31
CN103209983B (zh) 2016-04-13
JP5744215B2 (ja) 2015-07-08
EP2632926B1 (en) 2014-12-10
EP2447268A1 (en) 2012-05-02
RU2546661C2 (ru) 2015-04-10

Similar Documents

Publication Publication Date Title
CO6480954A2 (es) Método para producir una preparación altamente concentrada de inmunoglobulina de uso subcutaneo
MX2010002836A (es) Bortezomib y proceso para la produccion del mismo.
AR063347A1 (es) Formas cristalinas de docetaxel y proceso para su preparacion
BR112015005404A2 (pt) Formas polimórficas de enzalutamida e sua preparação
BR112013022625A2 (pt) quadros policristalinos, elementos policristalinos, e métodos relacionados
BR112012000304A8 (pt) processo para a desidratação de etanol para produzir eteno
BR112014008214A2 (pt) composto, processo de síntese de peptídeo em fase sólida para preparar um composto, processo, composição e uso do composto
BRPI1010128A2 (pt) "processo para a fabricação do 2,3,3,3 - tetrafluropropeno"
CA2818957A1 (fr) Procede d'elimination de derives a base de siloxane d'une phase organique liquide
CL2014000441A1 (es) Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer.
IN2012DN01968A (es)
WO2012042534A3 (en) Preparation of r-sitagliptin and intermediates thereof
ECSP10010499A (es) Proceso para la preparación de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida
MX2015010165A (es) Metodo para reducir el consumo de energia mediante acoplamiento termico.
CL2008001513A1 (es) Uso de hidrofobinas como auxiliares en la cristalizacion de un solido; proceso para la produccion de un solido por cristalizacion a partir de una fase acuosa y separando el solido formado desder la fase acuosa.
CL2012003371A1 (es) Compuestos intermediarios de la síntesis de agomelatina; y el procedimiento de obtención de agomelatina a partir de dichos compuestos intermediarios
MX337997B (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
BR112012026411A2 (pt) processo para preparar ditiina-tetracarboxi-diiminas
CL2012001081A1 (es) Procesos de preparcion de compuestos intermediarios en la sintesis de valsartan por hidrolisis de un ester utilizando salesde aluminio.
BR112012022928A2 (pt) beta-hidroxialquilamidas, processo para sua produção, bem como seu uso
AR083588A1 (es) Forma cristalina de 13-[(n-tert-butoxicarbonil)-2’-o-hexanoil-3-fenilsoserinil]-10-deacetilbaccatina iii y proceso para prepararla
EA201200150A1 (ru) Новые гербициды
BRPI0907545A2 (pt) Processo para a preparação contínua de 1, 3-dioxolan-2-ona
BR112013009176A2 (pt) processo para a síntese de álcoois quirais propargílicos.
EA201490536A1 (ru) Новая кристаллическая форма

Legal Events

Date Code Title Description
FC Refusal